Compare Eni SpA (E) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs TG Therapeutics Inc — how do they compare? Eni SpA trades at $56.11 (market cap $79.81B), while TG Therapeutics Inc trades at $55.27 (market cap $8.16B). The key difference: Eni SpA is far larger — about 9.8× TG Therapeutics Inc's market cap, and Eni SpA pays a 4.39% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and TG Therapeutics Inc for 15 Days on average.
| E | TGTX | |
|---|---|---|
Market Cap | $79.81B | $8.16B |
Volume | 365,912 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $57.61 | $59.06 |
52-Week Low | $34.03 | $26.94 |
Typical Hold Time | 53 Days | 15 Days |
Enterprise Value | $104.34B | $8.37B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.09, up 3.95% on the day, with mixed technical signals showing bearish moving averages but oversold short-term RSI. Fundamentally, the company shows attractive valuation metrics with P/E of 12.87 and EV/EBITDA of 4.18, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent news highlights strategic initiatives including humanoid robotics partnerships and fuel discount programs.
The stock presents value opportunity with strong cash flow generation and dividend yield, but faces headwinds from declining revenue trends and recent earnings misses. Analyst consensus leans cautious with 62% hold ratings, suggesting patience required for operational turnaround despite attractive valuation multiples.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
